{"id":"eu-stelara","_chembl":{"chemblId":"CHEMBL5857501","moleculeType":null,"molecularWeight":"542.39"},"_dailymed":null,"_scrapedAt":"2026-03-28T05:03:39.021Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779122966,"model":"claude-sonnet-4-5-20250929"},"description":"EU-STELARA® is a Phase 1 investigational drug developed by BioFactura Australia Pty Ltd. Limited public information is available about this early-stage therapeutic candidate, including its molecular target, mechanism of action, and intended therapeutic applications.","indications":{"approved":[{"status":"investigational","condition":null,"patientPopulation":null}]},"trialDetails":[{"nctId":"NCT04728360","phase":"PHASE3","title":"Comparative Study of BAT2206 With Stelara® in Patients With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2021-07-06","conditions":"Plaque Psoriasis","enrollment":556},{"nctId":"NCT04930042","phase":"PHASE3","title":"Efficacy, Safety, and Immunogenicity of AVT04 With Moderate-to-Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2021-06-03","conditions":"Psoriasis","enrollment":581},{"nctId":"NCT04744363","phase":"PHASE1","title":"Pharmacokinetics, Safety and Tolerability Study of AVT04 to EU Approved and US Licensed Stelara (Ustekinumab)","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2021-05-25","conditions":"Psoriasis","enrollment":294},{"nctId":"NCT04772274","phase":"PHASE1","title":"A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to European Union (EU) Sourced Stelara and United States of America (US) Sourced Stelara in Healthy Subjects","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2021-02-04","conditions":"Healthy","enrollment":201},{"nctId":"NCT04843631","phase":"PHASE1","title":"Bioequivalence Phase I Study of BFI-751 Compared With EU and US-STELARA® in Healthy Adults","status":"COMPLETED","sponsor":"BioFactura Australia Pty Ltd.","startDate":"2021-04-01","conditions":"Psoriasis","enrollment":216},{"nctId":"NCT04371185","phase":"PHASE1","title":"Comparative Study to Evaluate the Pharmacokinetics of BAT2206 vs Stelara® in Healthy Subjects","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2020-08-08","conditions":"Psoriasis","enrollment":270}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["STELARA® (ustekinumab)"],"phase":"phase_1","status":"active","brandName":"EU-STELARA®","genericName":"EU-STELARA®","companyName":"BioFactura Australia Pty Ltd.","companyId":"biofactura-australia-pty-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":1,"visitCount":2,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}